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Abstract 
Bone metastasis is a leading cause of morbidity and mortality in prostate cancer (PCa). While 
cancer stem-like cells have been implicated as a cell of origin for PCa metastases, the 
pathways which enable metastatic development at distal sites remain largely unknown. In this 
study, we illuminate pathways relevant to bone metastasis in this disease. We observed that 
cyclin A1 (CCNA1) protein expression was relatively higher in PCa metastatic lesions in 
lymph node, lung, and bone/bone marrow. In both primary and metastatic tissues, cyclin A1 
expression was also correlated with aromatase (CYP19A1), a key enzyme that directly 
regulates the local balance of androgens to estrogens. Cyclin A1 overexpression in the stem-
like ALDHhigh subpopulation of PC3M cells, one model of PCa, enabled bone marrow 
integration and metastatic growth. Further, cells obtained from bone marrow metastatic 
lesions displayed self-renewal capability in colony forming assays. In the bone marrow, 
Cyclin A1 and aromatase enhanced local bone marrow-releasing factors, including androgen 
receptor, estrogen and matrix metalloproteinase MMP9 and promoted hte metastatic growth 
of PCa cells. Moreover, ALDHhigh tumor cells expressing elevated levels of aromatase 
stimulated tumor/host estrogen production and acquired a growth advantage in the presence of 
host bone marrow cells. Overall, these findings suggest that local production of steroids and 
MMPs in the bone marrow may provide a suitable microenvironment for ALDHhigh PCa 
cells to establish metastatic growths, offering new approaches to therapeutically target bone 
metastases. 
 
   
 
Introduction 
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Malignant stem cells may arise within the normal stem cell population or through 
carcinogenic transformation of a differentiated cell type enabling the adoption of stem like 
features (1, 2, 3). It is believed that only a subset of cells, termed cancer stem cells, are 
capable of initiating metastatic dissemination to distant organs (3-6). Cancer stem cells have 
been identified in malignancies including leukemia, brain, breast, colon and prostate cancers 
(PCa) as well (2,4,7-12).  
 
In PCa, only rare, phenotypically distinct PCa tumor-initiating cells, also termed stem-like 
PCa cells have the capacity to form new tumors (4,7-9). Metastatic PCa remains a major 
clinical challenge, as most of PCa patients die from bone metastases (13,14). PCa are believed 
to favor the bone marrow, which are the unique sites enriched with hematopoietic cells, 
osteoblasts, stromal, extracellular matrixes and multiple cytokines (5,13,15,16). The stem-like 
PCa cells are believed to produce high levels of chemokine receptors which enable interaction 
of PCa with the infiltrated bone marrow cells to facilitate distant metastases (17,18, 19). The 
growth and metastases of stem-like PCa cells are also influenced by various types of steroid 
hormones including androgens and estrogens and their receptors (20-24). Recent reported 
studies suggest that estrogen and its receptor ERα are present in the hematopoietic stem cells 
(HSC) and bone cells (25-27). However, it remains largely unknown whether the steriod 
hormones may promote metastatic growth of the stem-like PCa cells in the bone marrow.  
 
Aromatase is a steroid biosynthesis enzyme which is encoded by CYP19A1 gene, and 
catalyzes the conversion from androgens to estrogen (28). Aromatase expression in prostate 
epithelial cells and the infiltrated inflammatory cells is induced by the cytokines, and is 
associated with the progression of prostate cancer (29). CYP19A1 expression is elevated in 
prostate cancer metastatic tissue with 30-fold higher than that in primary tumors (20,22,30). 
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Conversely, deletion of CYP19A1 alleles reduces incidence of PCa in mice after exposure to 
testosterone and estrogen (20).  
 
The cell surface markers that recognize cancer stem cells provide possibility to study the 
unique mechanisms underlying cancer metastases in mouse models (31,32). Aldehyde 
dehydrogenase 1 (ALDH1) is a detoxifying enzyme responsible for the oxidation of 
intracellular aldehydes and has emerged as an ideal marker for isolation of stem-like cells 
from heterogeneous tumors (33-36). As the ALDH activity is increased in cancer stem cell 
populations isolated from multiple myeloma, acute myeloid leukemia (15), breast cancer lung, 
head and neck, gastric and colorectal cancers and recently in PCa (37-46), it is therefore 
considered as a reliable marker for isolation of cancer stem cells. Importantly, isolated 
ALDHhigh stem-like PCa cells initiate growth of tumors in orthotopic mouse models (41). 
 
Cyclin A1 is an important cell cycle regulator and its expression is elevated in PCa (47,48). It 
acts as a co-regulator of AR on VEGF promoter activity to regulate VEGF expression (47,48). 
Induced overexpression of cyclin A1 in PC3 cells initiated metastatic growth in lymph node, 
lung and liver in subcutaneous and orthotropic xenograft mouse models (48). In metastatic 
PC3 cells, cyclin A1 is functionally associated with VEGF and MMP2/MMP9 (48). Recently, 
we report that cyclin A1 interacts with ERα to promote breast cancer progression in xenograft 
mouse model (49).  Cyclin A1 function is required for hematopoietic stem and progenitor 
cells (HSPC) to home to their bone marrow niches (50). In this study, we showed that 
ALDHhigh stem-like cells facilitate metastatic growth by utilizing cyclin A1 and aromatase to 
increase androgen to estrogen conversion and recruiting extracellular matrix 
metalloproteinases (MMP9) from the host bone marrow. 
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Materials and Methods 
Tissue Specimens, Tissue Microarrays, cDNA Microarrays, and CGH Arrays.  
Tissue microarrays containing primary PCa (n=17) and metastatic PCa lesions (n=43) from 14 
PCa patients, and paired BPH (n=48) vs. PCa tissues (n=48) from 48 patients were 
constructed at Department of Clinical Pathology and Cytology, Skåne University Hospital, 
Malmö. The mRNA expression data of cyclin A1 and aromatase (CYP19A1) were extracted 
from the cBioPortal database with GEO accession number: GSE21032 as described (51,52). 
The study was approved by the Ethics Committee, Lund University, and the Helsinki 
Declaration of Human Rights was strictly observed.  
 
Immunohistochemistry Analysis 
Immunohistochemistry on tumor tissue arrays was performed as previously described (47). 
The staining procedure was performed using a semiautomatic staining machine (Ventana ES, 
Ventana Inc., Tucson, AZ) as previously described (48).  
  
Cell culture and Generation of vectors and stable and transient transfection 
An androgen-insensitive cell line, PC3M cells were kindly provided by Dr. J Fidler 
(Department of Urology, MD Anderson Cancer Center, Houston, Texas, USA) (53).  The cell 
lines were authenticated by the suppliers. The PC3M cells were received 2011, and fresh-
frozen stocks were used. The total span of years in using PC3M cells in our labs is 
approximately three years. For transient transfection studies, pMSCV-cyclinA1-EGFP was 
generated by cloning the full-length (1.8 kb) human cyclin A1 cDNA into the EcoRI site of 
the pMSCV-EGFP construct (Clonetech Inc.).  
 
Prostate tumor spheroid formation assays 
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PC3M cells were cultured in polyhema-coated flasks at 5000/ml in spheroid medium 
modified from protocols used for mammo-sphere formation as described (54). To generate 
second passage spheres, cells derived from the first passage spheres were plated again at a 
density of 5x103 cells/ml and grown in culture medium for 7 days as mentioned above. 
 
ALDEFLUOR assay 
The ALDEFLUOR kit (StemCell Technologies, Vancouver, Canada) was used to isolate the 
population with a high ALDH enzymatic activity (stem-like ALDHhigh cells) according to 
manufacturers’ protocol. Cells were stained with 7AAD (BD Biosciences, San Jose, CA, 
USA) to distinguish viable cells from dead cells and analysis on CyAn™ ADP flow 
cytometer or FACS Aria (Beckman Coulter). FACS data were analyzed using FCS Express 
software (DeNovo Software, CA).  
 
Mouse model of PCa distant metastases 
The animal studies were approved by the Swedish Regional Ethical Animal Welfare 
Committee and the guidelines were strictly followed. Athymic NMRI nude male mice aged 
8–12 weeks (Taconic Europe, Denmark) were used. For intravenous injection of tumor cells, 
mice were sub-lethally irradiated with two doses of 2 Gy administered 2 hours apart using a 
137Cs source at a dose rate of 1Gy/min as described (55). Equal amount of ALDHhigh cells 
(1x105 cells /mouse) or unsorted PC3M cells (2x106 cells/mouse) were injected into mice via 
tail-veins. For intracardiac injection, 1x105 cells /mouse were injected into the left ventricle of 
anaesthetized mice (1% isoflurane through inhalation). In vivo imaging device (IVIS imaging 
system, PerkinElmer). For HLA-ABC antibody-based imaging, mice were injected 
intraperitoneally with 30 µg of HLA-ABC antibody conjugated with 680 DyLight NHS-ester 
(LifeTechnologies) (56).  
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Identification of metastatic PCa cells in the bone marrow of mice by FACS 
To identify metastatic PCa cells in the bone marrow of irradiated recipients after 
transplantation, bone marrow cells from long bones of the recipient mice were isolated and 
were assessed using FACS methods as described (50).  
 
Evaluation of ability of single cells from metastatic tumors of mice to form colony-forming 
unit using methylcellulose-based medium  
To assess the repopulating ability and differentiation potential of the BM progenitor cells or 
metastatic PCa cells in the bone marrow, we used a methylcellulose-based colony-forming 
assay according to the manufacturer’s description (MethoCult™, Stem Cell Technologies). 
Colonies containing 30 and more cells were scored after 14 days.  
   
Immunofluorescence analysis  
For immunofluorescence analysis, cell suspensions were fixed on slides in 4% 
paraformaldehyde (Merck KGaA, Germany) for 15 minutes at room temperature (RT).  The 
slides were stained with primary antibodies including anti-HLA (Biosite) and anti-cyclin A1 
(BD Pharmingen).  
  
Treatment of ALDHhigh or ALDHlow cells with 17-β-estradiol or DTH  
For estrogen treatment, ALDHhigh or ALDHlow populations were sorted from PC3M cells and 
were maintained in 10% charcoal stripped phenol red free medium (CSS) (Gibco, Life 
Technologies) for 24 hour prior to treatment with 17-β-estradiol at 10 nM and DTH at 5 nM 
(Sigma-Aldrich Inc.). The effects of 17-β-estradiol and DTH on ALDHhigh or ALDHlow cells 
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were determined using the nonradioactive tetrazolium dye-based proliferation assay (MTS) 
(Promega Biotech) according to the manufacturer’s protocol. 
 
Co-culture of ALDHhigh or ALDHlow cells with the bone marrow and measurement of estradiol 
production 
For MTS assay, ALDHhigh or ALDHlow cells were cultured in serum-free phenol red free 
RPMI medium containing 50% of the bone marrow extracts of NMRI-nude mice. The cells 
were cultured for 48 hours and were subjected for MTS assay. For measurement of estradiol 
production, Estradiol Assay kit (R&D Systems Ltd, Abingdon, UK) was used according to the 
manufacturer’s protocol. For treatment with Aromatase inhibitor, Type I aromatase inhibitor 
(Merck Millipore) was used at 100 nM concentration. Concentrations were determined by 
measuring absorbance on an Infinite M200 multimode microplate reader (Tecan Sunrise). 
Testosterone and estradiol levels were determined using an immunoassay from Roche 
Diagnostics (Estradiol III) on a Cobas 6000 Analyzer (Roche Diagnostics, USA).  
 
Statistical analysis 
Statistical analysis was performed. Distribution of overall survival (OS) was estimated by the 
method of Kaplan-Meier, with 95% confidence intervals. Differences between survival curves 
were calculated using the log-rank test using statistical program (SPSS, 16.0). 
Description of experimental procedures and methods are given in Supplemental Materials and 
Methods (Supplemental Information).  
 
Results 
Expression of cyclin A1 and aromatase in patients with PCa   
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Immunohistochemical analysis was performed to assess protein expression of cyclin A1 and 
aromatase on tissue microarrays (TMAs) consisting of begin prostate hyperplasia (BPH) 
(n=48 patients), primary PCa (n=65) and metastatic PCa in lymph nodes, bone marrows and 
lungs (n=43) from 14 PCa patients who suffered bone metastasis. Cyclin A1 expression was 
predominantly nuclear, while aromatase expression was cytoplasmic in primary and 
metastatic PCa tissues (Figure 1A). Expression of cyclin A1 was higher in primary PCa than 
in BPH (for cyclin A1, p<0.001) (Figure 1B). Metastatic lesions displayed increased cyclin 
A1 expression compared with that of primary PCa (p=0.019) (Figure 1C). Although 
aromatase expression did not show significant increase in metastatic PCa compared with 
primary tumors (Figure 1C), it was significantly higher in primary PCa than in BPH 
(p=0.001) (Figure 1 B). Further, expression of cyclin A1 was positively correlated with 
aromatase expression in both primary and metastatic PCa as determined by Spearman’s rank 
correlation test (R2= 0.398, p< 0.001).  
 
We next examined mRNA expression of cyclin A1 and aromatase using a PCa cohort 
consisting of primary (n=131) and metastatic (n=19) PCa tissues extracted from the public 
available databases (51). Cyclin A1 and aromatase mRNA expression remained to be similar 
between primary and metastatic PCa tissues (Figure 1D). Somatic mutations or amplifications 
in genes encoding cyclin A1 and aromatase appeared to be rare. Only 4% (8 out of 216) 
amplifications in gene encoding for cyclin A1 and 2% (4 out of 216) amplifications in 
CYP19A1 gene were observed (Figure 1E). This suggests that overexpression of cyclin A1 
and aromatase in PCa may be due to the alterations at protein levels. Nevertheless, we 
observed that a subset of patients with higher CYP19A1 expression suffered poorer BCR-free 
survival as compared with those with lower CYP19A1 (p<0.001) (Figure 1F). Cyclin A1 
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expression was not associated with disease-free survival of PCa patients in these two cohorts 
(p=0.348) (Figure 1F). 
 
Cyclin A1 promoted growth of “tumor spheres” in vitro  
The stem-like ALDHhigh and non-stem-like ALDHlow subpopulations of PC3M cells were 
sorted by FACS using the ALDEFLUOR assay (Figure 2A and B), and were examined for the 
expression of cyclin A1 and aromatase. Both ALDHhigh and ALDHlow cells expressed cyclin 
A1 and aromatase (Figure 2C). Next, the role of cyclin A1 in tumor-initiating property of 
stem-like cells was assessed. We employed 3-demension (3-D) culture systems, as this 
method is well-established for assessment of breast cancer stem cells (57, 58). PC3M cells 
that were stably transfected with pMSCV-EGFP or pMSCV-EGFP-A1 were seeded in 3-D 
medium and were cultured for a period of 7 days. One of the characteristics of the stem-like 
cells is the ability to form “tumor spheres”. PC3M cells expressing cyclin A1 formed larger 
size of “tumor spheres” with increased cell numbers as compared with the controls (p=0.03) 
(Figure 2D and E). We next re-plated the single cell suspensions prepared from the spheres to 
test their self-renewal ability. The re-plated cells expressing cyclin A1 again formed larger 
spheres with higher cell numbers compared with the controls (p=0.015) (Figure 2D and E). 
Further, PC3M cells expressing cyclin A1 contained higher frequency of ALDHhigh 
subpopulation (5.43±2.69%) with approximately 3-fold increase compared with the controls 
(1.89±0.85%) (p<0.001) (Figure 2F). This data suggests that PC3M cells contain stem-like 
cells and that cyclin A1 overexpression increases frequency of the tumor-initiating cells in 
vitro. 
 
Cyclin A1 and aromatase promote metastatic dissemination of ALDHhigh stem-like cells to 
the bone marrow in mouse xenografts 
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To investigate whether the ALDHhigh stem-like cells may invade to the bone marrow, we 
established an in vivo mouse model. Nude mice were sub-lethally irradiated with low dose γ-
irradiation to inhibit host immune function prior to the transplantation of the tumor cells. We 
observed that expression of aromatase and ERα was higher in ALDHhigh cells overexpressing 
cyclin A1 compared with the controls (Figure 3A). Equal amount of ALDHhigh subpopulations 
sorted from PC3M cells expressing the vectors were introduced into the irradiated mice via 
intravenously injection (Figure 3B). The human HLA-ABC antibody conjugated with 
fluorescent dye was administrated into the mice for bioluminescent in vivo imaging analysis 
(Figure 3C). Tumors that were positive to HLA-ABC fluorescent antibody were detected in 
both groups of mice using imaging device after 80 days post-transplantation (Figure 3C). We 
performed FACS analysis and confirmed that the transplanted cancer cells positive to HLA-
ABC integrated into the bone marrow (Figure 3D). There was clear trend that a higher 
frequency of ALDHhigh cells overexpressing cyclin A1 homed the host bone marrow 
compared with the controls (n=4 mice/per group) (P=0.076) (Figure 3D).  
 
Since the FACS analysis is dependent on the quality of HLA-ABC antibody and its ability to 
bind tumor-producing HLA-ABC antigens in vivo, therefore this method represents certain 
difficulties with large variations. We therefore examined expression of cytokeratins that 
specifically recognize human PCa cells in the bone marrow (Figure 3E). A significantly 
higher number of cytokeratins-positive cells and Ki-67-positive cells was observed in the 
bone marrow of mice which received ALDHhigh cells expressing cyclin A1 vector (for 
cytokeratins, p=0.024; for Ki-67, p<0.001) (Figure 3E, F, G and H). These data showed that 
ALDHhigh cells integrated into the bone marrow and that cyclin A1 overexpression enhanced 
metastatic growth of the ALDHhigh cells.   
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We transplanted unsorted PC3M cells expressing cyclin A1 or EGFP vector into the irradiated 
mice via intravenous injection. Metastatic tumors in prostate, lung and liver appeared in 3 out 
of 5 mice which received PC3M cells expressing cyclin A1, while a large subcutaneous tumor 
was formed near the proximal end of the tail in 1 out of 5 control mice (Supplemental Figure 
1). There was a clear trend that elevated levels of cyclin A1 in tumors were positively 
correlated with poorer overall survivals of the xenograft mice (Supplemental Figure 1). No 
metastases to the bone marrow were detected in these xenograft mice. We therefore induced 
unsorted PC3M cells expressing cyclin A1 or EGFP vectors into mice via intracardiac 
injection which allows tumor cells entering directly into systemic circulation, and homing to 
the bone marrow.  Tumor metastases were detected in both groups of mice after 33 days post-
transplantation (5 mice/group) using bioluminescent in vivo imaging analysis (Supplemental 
Figure 2A and B). FACS analysis revealed that HLA-ABC-positive PC3M cells integrated 
into the bone marrow (Supplemental Figure 2C and D). Overexpression of cyclin A1 
increased frequency of PC3M homing to the bone marrow relative to controls, as determined 
by using cytokeratins-stainings of tumor cells (P= 0.016 for CK5 and P= 0.0014 for CK20) 
(Supplemental Figure 3).  
 
Metastatic growth of ALDHhigh PC3M cells in the bone marrow through cyclin A1 and 
aromatase associated pathways 
We next wanted to assess whether metastatic lesions initiated by ALDHhigh PC3M cells may 
retain stem-like properties such as self-renewal and differentiation. We isolated bone marrow 
cells from the mice bearing bone marrow metastases initiated by ALDHhigh cells expressing 
cyclin A1 or control vector. The isolated bone marrow cells were then subjected to colony 
formation Unit (CFU) assay in the semi-solid MethoCult™ medium which is commonly used 
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for assessment of self-renewal and differentiation ability of the hematopoietic cells (Figure 
4A). Bone marrow cells containing PCa metastatic lesions isolated from the mice (4 
mice/group) formed colonies (Figure 4B). To access whether the CFUs might be derived from 
both host hematopoietic stem/progenitor cells, and metastatic ALDHhigh cells, single cell 
suspensions were prepared from the colonies and were examined for the co-expression of 
cyclin A1 and HLA-ABC, a specific human tumor antigen. We observed that the subset of 
cells collected from the CFUs indeed co-expressed cyclin A1 and HLA-ABC, and the signals 
were enhanced in cells overexpressing cyclin A1 (Figure 4C). By using the combination of 
Giemsa staining and visualization of EGFP positivity in CFUs, we further identified CFUs 
derived from ALDHhigh cells (Figure 4D, E, F and G). This suggests that the metastatic lesions 
derived from ALDHhigh cells are able to self-renewal and repopulate into new tumor cells in 
CFU assays, and this characteristic is similar to the host bone marrow hematopoietic 
stem/progenitor cells. Further, we observed that there was a higher proportion of PCa cells in 
the CFUs derived from the bone marrow samples of mice bearing metastases with elevated 
level of cyclin A1 as compared with the controls (p<0.001) (Figure 4H). These new findings 
showed that the metastatic lesions derived from ALDHhigh PC3M cells retained self-renewal 
and repopulating properties.  
 
We examined the expression of aromatase and ERα in the CFUs derived from the metastatic 
bone marrow of the xenograft mice. Expression of aromatase and ERα retained in the CFUs-
derived from the metastatic lesions initiated by the ALDHhigh cells, and was enhanced by 
overexpression of cyclin A1 (Figure 4I and J). The absence of both aromatase and ERα in the 
CFUs of tumor-free bone marrow was observed (Figure 4 I and J). In contrast, AR expression 
was absent in the CFUs derived from the metastatic lesions but was present in the CFUs of 
tumor-free bone marrow (Figure 4K), suggesting that AR is produced by the host bone 
Research. 
on February 28, 2016. © 2016 American Association for Cancercancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on February 26, 2016; DOI: 10.1158/0008-5472.CAN-15-2340 
13 
 
marrow microenvironment. We observed that overexpression of cyclin A1 was positively 
associated with the decreased apoptosis, as determined by examining the expression of 
cleaved caspase-3 in the CFUs derived from the metastatic PCa lesions (Figure 4L).  
 
Cyclin A1 overexpression in ALDHhigh cells increased MMP9 expression in the bone 
marrow cells 
We further examined aromatase expression in series bone marrow sections of the xenograft 
mice bearing metastases using immunohistochemical analysis. Approximately 10% 
aromatase-positive cells were observed in the metastatic bone marrow of control xenograft 
mice (Figure 5A and B).  Overexpression of cyclin A1 increased aromatase-positive cells by 
60% (p<0.001) and staining intensity of aromatase (Figure 5A, B and C). The integration of 
ALDHhigh cells overexpressing cyclin A1 into the bone marrow significantly increased MMP9 
expression in the host bone marrow (p=0.016) (Figure 5D, G and H). Similar to AR, MMP9 
expression was absent in ALDHhigh cells, but was present in the host bone marrow cells 
(Figure 5E and F). These data suggest that ALDHhigh cells with elevated level of cyclin A1 
influence the bone marrow-releasing factor such as MMP9.  
 
ALDHhigh stem-like subpopulation of PC3M cells are more sensitive to aromatase inhibition 
than the ALDHlow cells  
We further investigated whether the ability of ALDHhigh cells to initiate metastatic growth in 
the bone marrow is related to their stem-like characteristics with growth advantages. We 
subjected equal amount of ALDHhigh and ALDHlow cells sorted from PC3M cells expressing 
EGFP-cyclin A1 or control vectors to the MTS-based proliferation assays. The growth rate of 
ALDHhigh subpopulation was significantly higher with 20% increase compared with the 
ALDHlow cells (p=0.012) (Figure 6A). Overexpression of cyclin A1 increased growth of 
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ALDHhigh cells by 60% as compared with the ALDHlow cells (p<0.001) (Figure 6A). Further, 
overexpression of cyclin A1 increased growth rate only in ALDHhigh cells (p=0.012) but not 
in ALDHlow cells (Figure 6A). This suggests that ALDHhigh cells with cyclin A1 
overexpression have growth advantages over that of ALDHlow cells. Next, we inhibited 
aromatase production in ALDHhigh vs. ALDHlow cells using an irreversible type I aromatase 
inhibitor. Inhibition of aromatase reduced proliferation of control ALDHhigh cells (p=0.008) 
and ALDHhigh cells overexpressing cyclin A1 (p<0.001) (Figure 6B), but had no significant 
effect on ALDHlow cells. We further examined the effect of bone marrow microenvironment 
on the growth of ALDHhigh vs. ALDHlow cells. We co-cultured equal amount of the sorted 
cells with the bone marrow extracts of mice. ALDHhigh cells displayed higher ability to adapt 
and grow in the bone marrow-containing medium compared with the ALDHlow cells as 
determined by MTS proliferation assays (Figure 6C). Overexpression of cyclin A1 
significantly enhanced ability of ALDHhigh cells, but not that of ALDHlow cells to grow in the 
bone marrow-containing medium (Figure 6C). Next, we measured the concentration of 
estradiol, an end product of androgen to estrogen conversion, in ALDHhigh PC3M cells, in 
bone marrow cells alone and in co-cultures of ALDHhigh PC3M cells and bone marrow cells. 
Estradiol levels in ALDHhigh PC3M cells cultures were similar to that in the medium only 
(RPMI1640 containing 10%FBS) (Figure 6D), suggesting that ALDHhigh PC3M cells do not 
produce detectable levels of estrogen in vitro. Bone marrow cells produced detectable levels 
of estradiol, which were significantly increased in co-culture with ALDHhigh (Figure 6D and 
E). Overexpression of cyclin A1 further increased estradiol production (for BM alone vs. co-
culture of BM and ALDHhigh cells expressing EGFP, P<0.001; for co-culture of BM and 
ALDHhigh cells expressing EGFP-A1 vs co-culture of BM and ALDHhigh cells expressing 
EGFP, P=0.029) (Figure 6D). Inhibition of aromatase by aromatase inhibitor in ALDHhigh 
cells overexpressing cyclin A1 prior to the co-culture with the bone marrow cells in serum-
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free medium led to a significantly reduction in estradiol level in the co-culture (p<0.001) 
(Figure 6E).  
 
Discussion 
Increasing evidence has suggested that cancer stem cells are the cell origin to initiate distant 
metastases (4,5,59). However, the unique cellular pathways that enable cancer stem cells to 
establish metastatic lesions into the distant organs remain largely unknown. In this study, we 
observed that cyclin A1 protein expression was significantly higher in PCa metastatic lesions 
from PCa patients. In agreement with the previous reported study (60), our data also showed 
that aromatase was abnormally expressed in human PCa. Expression of both cyclin A1 and 
aromatase proteins was significantly higher in primary PCa than in BPH.  A subset of patients 
with upregulated aromatase mRNA expression suffered poorer BCR-free survival, although 
this finding was limited to fewer patients. Nevertheless, our present study adds new 
information on the clinical importance of aromatase expression in PCa progression.  
 
 
In this study, we found that ALDHhigh subpopulation of PC3M cells had higher growth ability 
compared with ALDHlow subpopulation. It has been shown that γ-radiation at low dose (2-4 
Gy) promoted tumor cell infiltration with no pronounced impact on host immune function in 
nude mice (55). The ALDHhigh subpopulation accounted for 1.89±0.85% of total PC3M cells 
initiated metastatic growth in the bone marrow of the irradiated immune-suppressive host 
mice, whereas unsorted PC3M cells homed to the bone marrow only when tumor cells were 
implanted by intracardiac injection. Intracardiac injection delivers tumor cells directly into 
systemic circulation, while tail vein injection necessitates that tumor cells pass through of 
lung and liver vasculatures before reaching the bone marrow. Thus our study establishes a 
robust mouse model and FACS-based analysis to study metastases of cancer cells and stem-
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like cancer cells to bone. Our findings are in agreement with the reported studies in breast 
cancer (37-39) and PCa (40,41), which suggest that rare subsets of cancer cells are sufficient 
to initiate metastases to distant organs.   
 
Although ALDHhigh PC3M cells alone are sufficient to initiate metastases into the bone/bone 
marrow, overexpression of cyclin A1 increased frequency of the integrated ALDHhigh cells by 
40-50%. These findings are coincident with that overexpression of cyclin A1 promoted 
proliferation of ALDHhigh subpopulation, but not ALDHlow subpopulation. Aromatase 
facilitates the metabolism of testicular testosterone and androstenedione to estrogen, and 
directly regulates the local balance of androgens to estrogens (61). Growing evidence suggests 
that the microenvironment has profound effects on cancer metastases to preferential 
tissues/organs. Aromatase is able to utilize exogenous testosterones and extracellular factors 
from the tumor-associated microenvironment to produce estradiols and other hormones (29).  
 
We found that the expression of bone marrow-releasing factors including AR, ERα, MMP9 
was induced as a result of metastatic integration of ALDHhigh cells. Our new data show that 
increased aromatase activity in ALDHhigh population in the context of the bone marrow 
microenvironment enhances estradiol production. Moreover, incorporation of a 
pharmacological inhibitor establishes the requirement for aromatase in estradiol production in 
our model. Overexpression of cyclin A1 further increases estradiol production, providing 
insight into how cyclin A1 overexpression in ALDHhigh cells can influence the tumor 
microenvironment in the bone marrow niches. We were unable to detect significant changes 
in the steady state levels of androgens in mono- or co-cultures of ALDHhigh cells and bone 
marrow cells (data not included).  
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Our study suggests that cyclin A1 is a key factor that regulates aromatase-associated 
pathways. However, the precise cellular mechanisms by cyclin A1 regulates aromatase 
expression remain to be further explored in the future studies. Taken together, our data 
suggest that the stem-like PCa cells express high levels of several key factors that facilitate 
metastatic homing to the bone marrow environment. Our study will provide new insights into 
the PCa bone metastases and help to design novel targeted therapy.  
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Figure legends 
Figure 1. Evaluation of the clinical importance of cyclin A1 and aromatase CYP19A1 in 
PCa patients. 
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(A,B,C). Immunohistochemical analysis of cyclin A1 and aromatase in primary PCa cancer 
specimens, and primary PCa cancer vs. PCa metastatic lesions in lymph nodes (LN), bone 
marrow (BM) and lung (Lung). Representative microphotographs are shown. Box-plot 
quantitative comparison of cyclin A1 and aromatase expression between BPH and primary 
cancer specimens in (B), and between primary and metastatic cancer specimens in (C). The 
paired Wilcoxon’s rank sum test analyses are shown. ***p<0.001, **p<0.01, *p<0.05. (D). 
Box plots presents expression of mRNA of cyclin A1 and aromatase in primary and 
metastatic PCa. (E). Gene alteration profiles for CYP19A1 and cyclin A1 in primary and 
metastatic patients. (F). Kaplan-Meier survival analysis to show biochemical recurrence 
(BCR). P values are indicated. 
 
Figure 2. The role of cyclin A1 in self-renewal and proliferation of PCa cancer stem-like 
cells. (A and B). Representative FACS plots of ALDHhigh vs ALDHlow cells within a total 
PC3M cells. (C). Immunoblot analysis of ALDHlow vs. ALDHhigh cells using antibodies as 
indicated. (D). Quantification of numbers of cells from the “tumor spheres” of the two groups 
as indicated. (E). Representative microphotographs show the morphologies of the “tumor 
spheres”. (F). Percentages of ALDHhigh cells expressing EGFP or EGFP-A1 are shown. SD± 
values indicate means of three independent experiments. *p=0.05 is indicated. 
 
Figure 3. Cyclin A1 overepxression promotes tumor metastasis by increasing 
proliferation and metastatic potential of ALDH-high cells.  
(A). Immunoblot analysis of ALDHhigh cells expressing pMSCV-EGFP or pMSCV-EGFP-A1 
using antibodies against cyclin A1 and aromatase and ERα. (B). A schematic chart depicts the 
procedure of transplantation of sorted ALDHhigh PC3M cells into irradiated mice through tail-
vein injection. (C). Representative images of the bioluminescent in vivo imaging using IVIS 
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imaging device. (D). Representative FACS plots show that the percentage of HLA-ABC-
positive metastatic PCa cells in the bone marrow of the two groups of mice. PC3M tumor 
cells were used as control as shown in the left (4 mice/group). (E and G). Representative of 
microphotographs of the bone marrow sections immune-stained with antibodies against 
cytokeratins in (E) and Ki-67 in (G). The enlarged areas are shown in the right. (F and H). 
The expression of cytokeratins and percentage of Ki-67 positive cells are quantified (3 
mice/group).  
 
Figure 4. Evaluate bone marrow metastasis initiated by ALDH-high PC3M cells.   
(A). A schematic chart depicts the experimental procedure. (B). Colony-Forming Unit counts 
(3-4 mice/group). (C). Cell suspensions were collected from the colonies as mentioned in (B) 
and were stained with antibodies against cyclin A1 and HLA-ABC. (D, E, F and G). Giemsa 
staining and fluorescence analysis of EGFP-expressing CFU cells with respective higher 
magnification images in (F,G).  (H). Percentages of EGFP-positive PCa cells in the total 
CFUs from each group are shown. (I, J, K and L).  Immunoblot analysis of  aromatase, ERα, 
AR and cleaved caspase-3 in CFUs derived from the bone marrows of mice received 
ALDHhigh cells expressing EGFP or EGFP-A1, and  from the bone marrow of irradiated 
tumor-free wild-type mice or cyclin A1-null mice  which served as controls.  
 
Figure 5. Cyclin A1 overexpression increases aromatase and MMP9 expression in mouse 
bone marrow.  
Immunostaining and statistical analysis of aromatase (A,B, C) and MMP9 (D) expression in  
bone marrow sections from xenograft recipients of ALDHhigh PC3M cells expressing EGPF or 
EGFP-A1 with tumors cells () (n=3 mice/group).  (E, F, G, H). Immunoblot analysis of 
MMP9 expression in (E) wild type mouse bone marrow, ALDHhigh EGFP and EGFP-A1 
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subpopulations of PC3M cells and (F) bone marrow and bone marrow-derived CFU-derived 
cell suspensions from ALDHhigh PC3M cells expressing EGPF or EGFP-A1 recipient 
xenograft mice. Immunoblot (G) and statistical analysis (H) of MMP9 expression in bone 
marrow ALDHhigh PC3M cells expressing EGPF or EGFP-A1 recipient mice (n=3/group). 
*p<0.05 and ***p<0.001 are indicated. 
 
Figure 6. The effect of inhibition of aromatase on ALDHhigh and ALDHlow cells and their 
bone marrow microenvironments.   
(A). The proliferation rates of equal amount of ALDHhigh vs. ALDHlow PC3M cells that 
express EGFP or EGFP-A1. (B). Proliferation rates were determined in ALDHhigh vs. 
ALDHlow cells that were treated with aromatase inhibitor or solvent (Ctrl). (C). Equal amount 
of ALDHhigh vs. ALDHlow cells were co-cultured with the bone marrow extracts and 
proliferation of the cells were determined using MTS assays. (D). Estradiol concentrations 
(pg/ml) were determined in different samples as indicated. The culture medium phenol red 
free RPMI1640 contains 10% serum. (E). The effect of aromatase inhibitor on estradiol 
concentrations in different samples. The phenol red free serum-free RPMI1640 medium was 
used. SD± values indicate means of three independent experiments. *p=0.05 and ***p<0.001 
are indicated.   
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